Merck Plans Phase III Prevymis CMV Trials In Renal Transplant Patients
Executive Summary
Merck & Co will start late-stage CMV prevention testing of first-in-class viral terminase complex inhibitor in renal transplant patients during the first half of 2018, following its launch for stem cell transplant recipients.
You may also be interested in...
New Anti-CMV Therapies Post-Transplant: Merck & Co Leads The Pack
Merck & Co’s investigational anti-CMV therapy letermovir is expected to be filed for approval later this year and could be the first of a new generation of anti-CMV therapies, following top-line Phase III data showing it reduced all-cause mortality in bone marrow transplant patients.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.